2/26/2009 11:48 AM ET
Millipore Corp. ( MIL ) on Thursday said that it has purchased the assets associated with Epitome Biosystems' EpiTag technology . The purchase price was not disclosed. Additionally, the acquisition will allow for the future development of other novel profiling technologies. For comments and feedback contact: editorial@rttnews.com

Millipore Purchases Assets Associated With Epitome Biosystems' EpiTag Technology

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company was founded in 1887 and is based in New York, New York.

Bristol Myers Squibb

WALTHAM , Mass. , Jan. 4 / PRNewswire / -- Epitome Biosystems announced today that it has signed a technology access and product development agreement with Bristol-Myers Squibb for use of Epitome 's proprietary EpiTag protein measurement platform .

Epitome Biosystems to Develop Biomarker Assay Panels for Bristol-Myers Squibb.

EMD Biosciences, Novagen Brand, manufactures and sells molecular biology tools--including gene splicers, protein purifiers, and more--that boost important research and development involving DNA, genes, proteins and other building blocks of life.

EMD Biosciences

Acquired

Epitome Biosystems is developing platform to synthesize kilobase- to megabase-length genetic code, orders of magnitude more rapidly and less expensively than currently available technology

Epitome Biosystems

MilliporeSigma

Illumina works to apply technologies and revolutionary assays to the analysis of genetic variation and function. It offers collaborative interactions, rapid delivery of solutions, and focuses on customers. Illumina's array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. The company was founded in 1998 and is based in San Diego, California.

Caris provides artificial intelligence integrated molecular science technology that assesses deoxyribonucleic acid, Ribonucleic acid, and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make personalized treatment decisions. It also researches and develops molecular profiling of blood and tissues. The company was founded in 2008 and is based in Irving, Texas.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Epitome Biosystems vs Lynx Therapeutics

Customers evaluate the quality of Epitome Biosystems's products using the following success metrics.